HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Money

Biotech stocks are on a tear again

The XBI is up 30% in six months, beating the S&P 500 by 24 percentage points — and the gap only widened in April.

By Endpoints News · Apr 15, 2026 · via Endpoints News
Biotech stocks are on a tear again

Image: Endpoints News

This is an aggregated industry headline. Read the full story at Endpoints News →

Tags
moneyformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
RA Capital banks $75M for a biotech SPAC
MoneyBioPharma Dive ↗
RA Capital banks $75M for a biotech SPAC
Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its …
May 21, 2026
Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model
MoneyFierceBiotech ↗
Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model
If any proof was needed that big money is still available for AI drug development, look no further than the 10…
May 13, 2026
CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion
MoneyFiercePharma ↗
CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another ind…
May 12, 2026